This website is being migrated. In case you don't find the information you are looking for, the old website can be found here. Thank you for reporting any anomalies to communication@ill.eu.

News

240522   Supercritical fluid dynamics_4x3.png
May 22, 2024 Unlocking the secrets of supercritical fluids
A study now published in Nature Communications brings remarkable insights into the enigmatic behaviour of supercritical fluids, a hybrid state of matter occupying a unique space between liquids and gases, and arising in domains ranging from the pharmaceutical industry to planetary science. The obtained results are at the limit of current experimental possibilities and could only be obtained in a high-flux neutron source such as the ILL.
radioisotopes.png
May 17, 2024 ILL is the chosen partner of Novartis to deliver a new cancer treatment drug
The Swiss company NOVARTIS announced at the Choose France Summit the desire to establish a partnership with the ILL, already a partner of other pharmaceutical companies for radioisotope production for cancer treatment and research. This is part of a plan to create a production unit intended to supply the French market with the first radioligand therapy (RLT) drug for the treatment of metastatic prostate cancer, an investment of close to 30 million euros in France.
molecular_moonlander_1.jpg
April 11, 2024 A molecular moonlander: insight into molecular motion on surfaces at the nanoscale
Using neutron spectroscopy data taken at ILL, researchers achieved a novel understanding of molecular movement at the nanoscale, providing new insights that may impact the design of future materials and technologies. The study has just been published in the Nature Portfolio open access journal Communications Chemistry – and is featured (as a banner) on the journal homepage.